RxDoctor Payments Data

Christina Duncan-Lothamer, DO

Obstetrics & Gynecology · Fort Wayne, INNPI 1891132098

Payments from drug & device makers

$4,277in general payments, 2019–2025

Across 32 payments — averaging $133.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$2K
  • AstraZeneca$405
  • GSK$369
  • Myriad Genetic Laboratories, Inc.$302
  • Tesaro, Inc.$242
  • Genmab U.S., Inc.$199
  • plus $748 from 10 others

What the payments were for

  • Food & beverage$2,313100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,277 in reported general payments places this provider in the 85th percentile of 743 obstetrics & gynecology providers in Indiana.

See all obstetrics & gynecology providers in Indiana

Medicare billing

Part B allowed, 2024
$76,121
Medicare patients
148
Services billed
721

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LynparzaOlaparib20$393,253
ZejulaNiraparib Tosylate14$363,074
Everolimus13$46,064
EliquisApixaban18$14,127
Dexamethasone53$1,345
Clobetasol Propionate26$921
Ondansetron OdtOndansetron42$905
Ondansetron Hcl58$708
Prochlorperazine Maleate41$377
Lidocaine-PrilocaineLidocaine/Prilocaine27$362
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst15$221
Ibuprofen45$199
Nystatin12$160
Oxycodone Hcl50$86
Fluconazole11$37

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaLynparza$405$393,25320 claims
GSKZejula$369$363,07414 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 743 obstetrics & gynecology providers in Indiana.

Other obstetrics & gynecology in Fort Wayne

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →